Dall, Genevieve V.
Vieusseux, Jessica
Seyed-Razavi, Yashar
Godde, Nathan
Ludford-Menting, Mandy
Russell, Sarah M.
Ashworth, Alan
Anderson, Robin L.
Risbridger, Gail P.
Shackleton, Mark
Britt, Kara L. http://orcid.org/0000-0001-6069-7856
Funding for this research was provided by:
Victorian Cancer Agency
National Health and Medical Research Council
National Breast Cancer Foundation
Article History
Received: 23 May 2020
Accepted: 11 July 2020
First Online: 21 July 2020
Compliance with ethical standards
:
: Alan Ashworth has the following disclosures: A.A. is a shareholder in Tango Therapeutics and consultant for AtlasMDX, Third Rock Ventures, Pfizer, ProLynx and Bluestar, a SAB Member of Genentech and Gladiator, and receives grant support from Sun Pharma and AstraZeneca. A.A. holds patents on the use of PARP inhibitors held jointly with AstraZeneca from which he has benefitted financially (and may do so in the future) through the ICR Rewards to Inventors Scheme.